GE HealthCare Technologies (NASDAQ:GEHC) Price Target Lowered to $65.00 at JPMorgan Chase & Co.

GE HealthCare Technologies (NASDAQ:GEHC) had its target price decreased by equities research analysts at JPMorgan Chase & Co. from $80.00 to $65.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s target price indicates a potential upside of 6.84% from the company’s previous close.

A number of other equities analysts also recently commented on GEHC. Bank of America lifted their price objective on GE HealthCare Technologies from $82.00 to $92.00 and gave the stock a “neutral” rating in a research report on Monday, January 5th. UBS Group downgraded GE HealthCare Technologies from a “neutral” rating to a “sell” rating and lifted their price objective for the stock from $73.00 to $77.00 in a research report on Thursday, January 15th. Oppenheimer reiterated an “outperform” rating and set a $85.00 price objective on shares of GE HealthCare Technologies in a research report on Thursday. Citigroup reduced their price objective on GE HealthCare Technologies from $80.00 to $65.00 and set a “neutral” rating on the stock in a research report on Thursday. Finally, Piper Sandler cut their target price on GE HealthCare Technologies from $96.00 to $88.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. Eight research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $80.67.

GE HealthCare Technologies Trading Up 2.3%

GE HealthCare Technologies stock traded up $1.35 during trading on Thursday, reaching $60.84. 10,025,557 shares of the company were exchanged, compared to its average volume of 3,890,753. GE HealthCare Technologies has a 52-week low of $58.75 and a 52-week high of $89.77. The company has a market capitalization of $27.76 billion, a P/E ratio of 13.34, a PEG ratio of 1.55 and a beta of 1.17. The company has a debt-to-equity ratio of 0.91, a current ratio of 1.37 and a quick ratio of 1.13. The stock’s 50 day simple moving average is $73.72 and its two-hundred day simple moving average is $77.64.

GE HealthCare Technologies (NASDAQ:GEHC) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $0.99 EPS for the quarter, missing analysts’ consensus estimates of $1.07 by ($0.08). GE HealthCare Technologies had a return on equity of 21.35% and a net margin of 10.11%.The company had revenue of $5.13 billion for the quarter, compared to analysts’ expectations of $5.03 billion. During the same quarter in the previous year, the business posted $1.01 EPS. The business’s quarterly revenue was up 7.4% compared to the same quarter last year. GE HealthCare Technologies has set its FY 2026 guidance at 4.800-5.000 EPS. On average, equities research analysts expect that GE HealthCare Technologies will post 5 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Frank R. Jimenez acquired 1,750 shares of the company’s stock in a transaction dated Thursday, April 30th. The stock was acquired at an average cost of $60.45 per share, with a total value of $105,787.50. Following the completion of the purchase, the insider owned 93,932 shares of the company’s stock, valued at $5,678,189.40. This represents a 1.90% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Peter J. Arduini bought 4,169 shares of the stock in a transaction that occurred on Thursday, April 30th. The shares were bought at an average cost of $59.92 per share, with a total value of $249,806.48. Following the completion of the purchase, the chief executive officer directly owned 259,424 shares in the company, valued at $15,544,686.08. This represents a 1.63% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders own 0.36% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of GEHC. Empowered Funds LLC grew its stake in GE HealthCare Technologies by 6.1% during the 1st quarter. Empowered Funds LLC now owns 28,848 shares of the company’s stock worth $2,328,000 after purchasing an additional 1,665 shares in the last quarter. Acadian Asset Management LLC acquired a new position in GE HealthCare Technologies during the 1st quarter worth $259,000. Cresset Asset Management LLC lifted its holdings in GE HealthCare Technologies by 12.5% during the 2nd quarter. Cresset Asset Management LLC now owns 7,802 shares of the company’s stock worth $578,000 after buying an additional 865 shares during the last quarter. Jump Financial LLC lifted its holdings in GE HealthCare Technologies by 317.6% during the 2nd quarter. Jump Financial LLC now owns 28,132 shares of the company’s stock worth $2,084,000 after buying an additional 21,396 shares during the last quarter. Finally, Gamco Investors INC. ET AL lifted its holdings in GE HealthCare Technologies by 8.6% during the 2nd quarter. Gamco Investors INC. ET AL now owns 4,041 shares of the company’s stock worth $299,000 after buying an additional 320 shares during the last quarter. 82.06% of the stock is owned by institutional investors and hedge funds.

More GE HealthCare Technologies News

Here are the key news stories impacting GE HealthCare Technologies this week:

• Positive Sentiment: Some investors and commentators argue the pullback is a buying opportunity given compressed valuation and the stock trading well below consensus targets. GE HealthCare Just Crashed 13% on a Guidance Cut. Here’s the Case for Buying the Dip
• Positive Sentiment: BTIG continues to rate GEHC a “buy” after trimming its target to $80, signaling further upside from current levels for investors who focus on longer?term recovery. BTIG Research PT Cut
• Positive Sentiment: Wells Fargo kept an overweight stance even while lowering its target to $75, showing some analysts still see meaningful upside despite near?term headwinds. Wells Fargo PT Cut
• Neutral Sentiment: Management announced an operational reorganization (combining Imaging and AVS into Advanced Imaging Solutions) and executive changes aimed at improving execution — a structural move that could help margins over time but is not an immediate fix. GE HealthCare operational updates press release
• Neutral Sentiment: Top?line: Q1 revenue beat estimates ($5.13B vs. ~$5.03B), showing demand resilience in Imaging, AVS and Pharma Diagnostics — positive for growth outlook but offset by margin pressure. GE HealthCare Q1 press release & slide deck
• Negative Sentiment: Profitability: Q1 EPS missed (reported $0.99 vs. ~$1.07 expected) and management trimmed FY26 EPS guidance to $4.80–$5.00 (below consensus). Those misses and the guidance cut triggered the recent steep decline and remain the main reason for investor caution. Reuters: GE HealthCare cuts annual profit forecast
• Negative Sentiment: Cost headwinds: Management cited inflation, higher chip/oil/freight costs, tariffs and supplier issues that pressured margins — analysts and articles highlight execution and inflation risk as key near?term negatives. WSJ: GE HealthCare cuts outlook as chip, oil prices surge
• Negative Sentiment: Some sell?side moves trimmed targets and ratings (Citigroup cut its target to $65 and moved to neutral), reflecting reduced near?term conviction and adding pressure to sentiment. Citigroup PT cut
• Negative Sentiment: Analyst/market writeups emphasize execution risk after Q1 and the guidance cut, suggesting sustained volatility until margin recovery or clearer evidence of execution improvement. Seeking Alpha: Inflation and execution risks weigh on outlook

GE HealthCare Technologies Company Profile

GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.